The potential of serum neurofilament as biomarker for multiple sclerosis
| Autor: | Eva Havrdova, Stefan Bittner, Jiwon Oh, Frauke Zipp, Mar Tintoré |
|---|---|
| Přispěvatelé: | Institut Català de la Salut, [Bittner S, Zipp F] Department of Neurology, Focus Program Translational Neuroscience (FTN) and Immunotherapy (FZI), Rhine-Main Neuroscience Network (rmn2), University Medical Center of the Johannes Gutenberg University Mainz, Mainz 55131, Germany. [Oh J] Division of Neurology, Department of Medicine, St Michael’s Hospital, University of Toronto, Toronto, Ontario M5S 3H2, Canada. [Kubala Havrdová E] Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Prague 116 36, Czech Republic. [Tintoré M] Servei de Neurologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus |
| Rok vydání: | 2021 |
| Předmět: |
Oncology
medicine.medical_specialty Treatment response Multiple Sclerosis Neurofilament Filaments citoplasmàtics Disease neurofilament Updates Neurofilament Proteins Internal medicine medicine Humans aminoácidos péptidos y proteínas::proteínas::aminoácidos péptidos y proteínas::proteínas::proteínas del tejido nervioso::proteínas de neurofilamentos [COMPUESTOS QUÍMICOS Y DROGAS] Longitudinal Studies Subclinical disease Diagnosis::Prognosis [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT] Esclerosi múltiple - Imatgeria per ressonància magnètica diagnóstico::pronóstico [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS] Other subheadings::Other subheadings::/diagnostic imaging [Other subheadings] AcademicSubjects/SCI01870 business.industry therapy response Multiple sclerosis Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases CNS::Multiple Sclerosis [DISEASES] biomarkers Otros calificadores::Otros calificadores::/diagnóstico por imagen [Otros calificadores] Amino Acids Peptides and Proteins::Proteins::Amino Acids Peptides and Proteins::Proteins::Nerve Tissue Proteins::Neurofilament Proteins [CHEMICALS AND DRUGS] Prognosis medicine.disease Esclerosi múltiple - Prognosi Magnetic Resonance Imaging Clinical trial Early results enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple [ENFERMEDADES] Biomarker (medicine) AcademicSubjects/MED00310 Neurology (clinical) business |
| Zdroj: | Brain Scientia |
| ISSN: | 1460-2156 0006-8950 |
| DOI: | 10.1093/brain/awab241 |
| Popis: | Multiple sclerosis is a highly heterogeneous disease, and the detection of neuroaxonal damage as well as its quantification is a critical step for patients. Blood-based serum neurofilament light chain (sNfL) is currently under close investigation as an easily accessible biomarker of prognosis and treatment response in patients with multiple sclerosis. There is abundant evidence that sNfL levels reflect ongoing inflammatory-driven neuroaxonal damage (e.g. relapses or MRI disease activity) and that sNfL levels predict disease activity over the next few years. In contrast, the association of sNfL with long-term clinical outcomes or its ability to reflect slow, diffuse neurodegenerative damage in multiple sclerosis is less clear. However, early results from real-world cohorts and clinical trials using sNfL as a marker of treatment response in multiple sclerosis are encouraging. Importantly, clinical algorithms should now be developed that incorporate the routine use of sNfL to guide individualized clinical decision-making in people with multiple sclerosis, together with additional fluid biomarkers and clinical and MRI measures. Here, we propose specific clinical scenarios where implementing sNfL measures may be of utility, including, among others: initial diagnosis, first treatment choice, surveillance of subclinical disease activity and guidance of therapy selection. Bittner et al. discuss the association of emerging biomarker serum neurofilament light chain (sNfL) with clinical activity, disease progression, MRI measures and therapeutic interventions in multiple sclerosis. They propose specific scenarios implementing sNfL for individualized clinical decision-making. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|